Ge Long Hui A P P·2025-07-22 10:49Core Viewpoint - Fosun Pharma is establishing a new nuclear medicine business platform, Xingrui Jingxuan, to enhance its innovative product pipeline and strengthen team cohesion and competitiveness [1][4]. Investment Structure - The initial registered capital of the new company is set at RMB 133.5 million, with contributions from Fosun Pharma and its subsidiaries, Chengdu Biocity Jingchuang Fund, co-investment platform, and incentive platform [1]. - The ownership distribution post-establishment will be approximately 89.89% for Fosun Pharma (or its subsidiaries), 2.62% for Chengdu Biocity Jingchuang Fund, 1.57% for the co-investment platform, and 5.92% for the incentive platform [1]. Co-Investment and Incentive Plans - A co-investment platform will be established with a total contribution of RMB 2.1 million from six participants, including senior management [2]. - An incentive platform will be created with an investment of RMB 7.9 million, which will be used for the initial incentive plan and potential future equity incentive plans [2][3]. Incentive Plan Details - The initial incentive plan will grant a total of 4.2 million options to six incentive targets, including senior management, with specific allocations for each [3]. - The options, if fully exercised, will correspond to RMB 4.2 million of the registered capital, representing approximately 3.15% of the initial registered capital of the new company [3]. Business Focus - The new company aims to develop integrated diagnostic and therapeutic nuclear medicine products in the oncology field through self-research and collaborative development [4].